A Phase II Study of Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
This study is testing an oral medication called cabozantinib to see how well it shrinks advanced lung cancer with specific genetic changes. Doctors want to learn if this targeted medicine can stop cancer cells from growing and spreading.
You may be able to join if you have advanced non-small cell lung cancer with certain genetic changes like RET, ROS1, or NTRK fusions. However, you cannot join if you have taken cabozantinib before or had recent cancer treatments within the past few weeks.
Participants will take the study medication by mouth and have their health and tumor response closely monitored by the study team. Doctors will check for any side effects and see how effective the treatment is at fighting your cancer.
This study is currently recruiting participants and takes place in multiple locations across New Jersey, United States. Your care team can help you find the closest participating clinic.
- 1Tests an oral medication called cabozantinib for advanced lung cancer
- 2Focuses on patients with specific gene changes like RET, ROS1, or NTRK fusions
- 3Currently recruiting patients at study locations in New Jersey
Related video
Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.